Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

NCT02175602

completedphase_1

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

NCT02095860

completedphase_1

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

NCT02108639

completedphase_1

Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

NCT02045966

completedphase_1

Drug Interaction & Methadone & Buprenorphine

NCT02045693

Clinical Trials (5)

Showing 5 of 5 trials

NCT02175602Phase 1

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

Completed

NCT02095860Phase 1

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

Completed

NCT02108639Phase 1

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Completed

NCT02045966Phase 1

Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

Completed

NCT02045693Phase 1

Drug Interaction & Methadone & Buprenorphine

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5